Skip to main content
. Author manuscript; available in PMC: 2016 Jun 21.
Published in final edited form as: Nat Nanotechnol. 2015 Dec 21;11(3):295–303. doi: 10.1038/nnano.2015.292

Figure 4. eCPMV treatment efficacy in B16F10 lung model is immune-mediated.

Figure 4

a, eCPMV inhalation did not significantly affect tumour progression when mice lack Il-12 (n = 7 eCPMV, 8 PBS). b, Treatment efficacy was also abrogated in the absence of Ifn-γ (n = 5/group). c, NOD/scid/Il2R-γ−/− mice lacking T, B, and NK cells also failed to respond to eCPMV inhalation therapy (n = 5/group). d, Depletion of neutrophils with Ly6G mAb abrogates treatment efficacy (n = 5/group). Data for bar graphs calculated using unpaired Student’s t-test with p <0.05 as *, p <0.01 as **, and p <0.001 as ***.